CEO Desmond Adam Keeps Buying Selectis Health Shares at Half‑Price, Bolstering Investor Confidence in Healthcare REIT Growth.

Insider Buying Builds Confidence in Selectis Health’s Growth Potential

CEO Desmond Adam has steadily increased his stake in Selectis Health over the past year, adding more than 53,000 shares through a series of low‑price purchases. The most recent trade, on 31 December 2025, saw Adam buy 1,300 shares at $2.25—well below the current market price of $3.88. This buying spree, spread across 23 transactions since February, signals that Adam remains optimistic about the REIT’s ability to capitalize on its healthcare‑focused portfolio and the broader real‑estate market.

What This Means for Investors

Adam’s consistent purchases are a bullish cue, suggesting he believes the market is undervaluing Selectis Health’s assets. For shareholders, his activity implies confidence that the company will continue to deliver steady cash flows and potentially expand its portfolio of healthcare properties. The fact that his average purchase price has stayed near $2.00, while the stock trades near $4.00, provides a built‑in margin for upside. However, investors should monitor for any significant change in the company’s fundamentals, such as shifts in debt levels or tenant mix, which could alter the valuation dynamics.

Market Sentiment and Broader Insider Activity

While Adam’s buying is a positive signal, overall market sentiment around the stock remains neutral, with a sentiment score of –0 and no significant buzz on social media. Company‑wide insider activity shows a mix of holdings and purchases, notably Lance Baller’s recent 6,192‑share purchase at $2.20 on 18 December 2025. This cohort of insiders buying at similar price points indicates a shared belief in the REIT’s trajectory. The lack of aggressive selling or large block trades also suggests stability among the leadership.

Strategic Outlook and Potential Catalysts

Selectis Health’s current 52‑week high of $4.50 and a market cap of roughly $12 million place it within a niche segment of healthcare real‑estate REITs. The company’s recent engagement with Black Pearl Equities, which has launched a tender offer for up to all shares, could become a catalyst. If the offer proceeds, it may trigger a temporary spike in liquidity and valuation, providing a potential exit or upside for long‑term holders. Until then, Adam’s incremental purchases and the company’s stable cash‑flow profile provide a foundation for cautious optimism among investors seeking exposure to the intersection of real estate and healthcare.

Bottom Line

Desmond Adam’s buying activity, coupled with other insider purchases at discount levels, underscores confidence in Selectis Health’s growth prospects. While market sentiment remains neutral, the company’s solid fundamentals and potential acquisition interest offer a compelling narrative for investors looking at REITs with a healthcare focus.